Literature DB >> 12872389

[Clinical observation on 103 patients of severe acute respiratory syndrome treated by integrative traditional Chinese and Western Medicine].

Lin Lin1, Yun Han, Zhi-min Yang.   

Abstract

OBJECTIVE: To observe the effect of 103 patients of severe acute respiratory syndrome (SARS) treated by integrative traditional Chinese and western medicine.
METHODS: Alimentotherapy, respiratory auxiliaring ventilation, anti-infective and glucocorticoid methods were used in western medicine; Chinese herbal medicine was used according to syndrome differentiation in traditional Chinese medicine. Descriptive statistical analyses were performed.
RESULTS: Of the 103 patients, 77 were identified as severe cases and 29 were admitted to the intensive care unit. A total of 96 patients (93.2%) were cured, 7 patients died (6.8%). The mean time between onset of feverishness and improvement was 6.72 +/- 3.95 days; 94 successful responses to therapy could be demonstrated by serial chest radiographs showing the resolution of lung opacities during 18.13 +/- 8.99 days, 2 of whom showed fibroid cord-like changes.
CONCLUSION: In terms of traditional Chinese medicine theory, SARS is referred to "infectious febrile disease", the therapeutic strategies of integrative traditional Chinese and western on SARS have been shown effective, and traditional Chinese medicine played a positive role in it.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872389

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  12 in total

Review 1.  Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence.

Authors:  Ming-Ming Zhang; Xue-Mei Liu; Lin He
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

Review 2.  Current situation and progress in integrative medicine in China.

Authors:  Ai-ping Lu; Xiao-rong Ding; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

Review 3.  Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

Authors:  Pawan K Agrawal; Chandan Agrawal; Gerald Blunden
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

4.  Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial.

Authors:  Jiayang He; Zhengtu Li; Wanyi Huang; Wenda Guan; Hongxia Ma; Zi Feng Yang; Xinhua Wang
Journal:  BMJ Open       Date:  2019-04-02       Impact factor: 2.692

Review 5.  Treatment of severe acute respiratory syndrome.

Authors:  S T Lai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

6.  Identification of natural compounds with antiviral activities against SARS-associated coronavirus.

Authors:  Shi-You Li; Cong Chen; Hai-Qing Zhang; Hai-Yan Guo; Hui Wang; Lin Wang; Xiang Zhang; Shi-Neng Hua; Jun Yu; Pei-Gen Xiao; Rong-Song Li; Xuehai Tan
Journal:  Antiviral Res       Date:  2005-07       Impact factor: 5.970

7.  Artemisia annua: Trials are needed for COVID-19.

Authors:  Faiz Ul Haq; Muhammad Roman; Kashif Ahmad; Saeed Ur Rahman; Syed Murtaza Ali Shah; Naveed Suleman; Sami Ullah; Iftekhar Ahmad; Wajahat Ullah
Journal:  Phytother Res       Date:  2020-05-27       Impact factor: 6.388

Review 8.  The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?

Authors:  Andréa D Fuzimoto; Ciro Isidoro
Journal:  J Tradit Complement Med       Date:  2020-05-30

9.  Investigation on ultrasound assisted extraction of saikosaponins from Radix Bupleuri.

Authors:  Shuna Zhao; Kin-Chor Kwok; Hanhua Liang
Journal:  Sep Purif Technol       Date:  2006-12-15       Impact factor: 7.312

Review 10.  Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection.

Authors:  A Berger; Ch Drosten; H W Doerr; M Stürmer; W Preiser
Journal:  J Clin Virol       Date:  2004-01       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.